==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1210 details
Primary information
ThPP IDTh1028
Therapeutic Peptide/Protein NameTenecteplase
SequenceSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKS view full sequnce in fasta
Functional ClassificationIb
Molecular Weight58951.2
Chemical FormulaC2561H3919N747O781S40
Isoelectric Point7.61
Hydrophobicity-0.528
Melting Point (℃)60
Half Life1.9 hours (mammalian reticulocytes, in vitro)
DescriptionTenecteplase(527 amino acid) is a glycoprotein developed by introducing the following modifications to the complementary DNA for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.
Indication/DiseaseTo treat myocardial infarction and lysis of intracoronary emboli.
PharmacodynamicsTenecteplase is a fibrin-specific tissue-plasminogen activator. It binds to fibrin rich clots and cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Mechanism of ActionTenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance99 - 119 mL/min [acute myocardial infarction patients]
CategoriesFibrinolytic Agents
Patents NumberCA2129660
Date of Issue28/06/05
Date of Expiry28/05/13
Drug InteractionAprotonin may antagonize the effect of Tenecteplase. Monitor for decreased effects of Tenecteplase.
TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1,Plasminogen activator inhibitor 2,Tetranectin,Keratin, type II cytoskeletal 8,Annexin A2,Calreticulin,Calnexin,Prolow-density lipoprotein
Information of corresponding available drug in the market
Brand NameTNKase
CompanyGenentech Inc
Brand DiscriptionTNKase is a tissue plasminogen activator produced by recombinant DNA technology using an established mammalian cell line of Chinese Hamster Ovary cells. Tenecteplase(527 amino acid) is a glycoprotein developed by introducing the following modifications to
Prescribed forTo prevent death from a heart attack (acute myocardial infarction).
Chemical NameN.A.
FormulationEach vial of TNKase nominally contains 52.5 mg Tenecteplase, 0.55 g L-arginine, 0.17 g phosphoric acid, and 4.3 mg polysorbate 20, which includes a 5% overfill. Each vial will deliver 50 mg of Tenecteplase.
Physcial AppearnceSterile, white to off-white, lyophilized powder
Route of AdministrationIntravenous Injection
Recommended DosageThe recommended total dose should not exceed 50 mg and is based upon patient weight. For less than 60 kg of body weight recommended dose is 30 mg of TNKase. Similarly 35 mg for 60-70 kg, 40 mg for 70-80 kg, 45 mg for 80-90 kg and 50 mg for more than 90 kg.
ContraindicationActive internal bleeding, History of cerebrovascular accident
Side EffectsNausea, vomiting; or fever.
Useful Linkhttp://www.drugs.com/mtm/tnkase.html
PubMed ID16488800, 16380055, 16084152, 15744554, 15650539
3-D StructureTh1028 (View) or (Download)